Download PDF
Semin Respir Crit Care Med 2000; Volume 21(Number 05): 451-462
DOI: 10.1055/s-2000-9407
Copyright © 2000 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Evaluation and Management of the Complications of Lung Cancer Treatment

Mei-Lin W. Ah-See1 , Stephen G. Spiro2
  • 1Clinical Oncology, The Middlesex Hospital, University College London Hospitals, London, United Kingdom
  • 2Department of Respiratory Medicine, The Middlesex Hospital, University College London Hospitals, London, United Kingdom
Further Information

Publication History

Publication Date:
31 December 2000 (online)

    Permissions and Reprints

ABSTRACT

The principal treatment-related complications encountered in the management of lung cancer are presented with particular reference to surgery, radiotherapy, and chemotherapy. The clinical features, risk factors, and management of the complications are discussed.

KEYWORD

Lung cancer - surgery - radiotherapy - chemotherapy - complications

REFERENCES

  • 1 McIntosh H C, Spitz S. A study of radiation pneumonitis.  AJR . 1939;  41 605-615
    PubMedGoogle Scholar
  • 2 Van der Kogel A J, Ang K K. Complications related to radiotherapy. In: Peckham M, Pinedo H, Veronesi U, eds. Oxford Textbook of Oncology Oxford: Oxford University Press, 1995: 2295-306
    Google Scholar
  • 3 Pearson F G. Current status of surgical resection for lung cancer.  Chest . 1994;  106 337-339S
    PubMedGoogle Scholar
  • 4 Silverberg E, Boring C C, Squires T S. Cancer Statistics.  CA Cancer J Clin . 1990;  40 9-26
    PubMedGoogle Scholar
  • 5 Deslauriers J, Ginsberg R J, Fournier B. Prospective assessment of 30-day operative morbidity for surgical resections in lung cancer.  Chest . 1994;  106 329-330S
    PubMedGoogle Scholar
  • 6 Ginsberg R J, Hill L D, Eagan R T. Modern thirty-day operative mortality for surgical resection in lung cancer.  J Thorac Cardiovasc Surg . 1983;  86 654-658
    CrossrefPubMedGoogle Scholar
  • 7 Markos J, Mullan B P, Hillman D R. Preoperative assessment as a predictor of mortality and morbidity after lung resection.  Am Rev Respir Dis . 1989;  139 902-910
    CrossrefPubMedGoogle Scholar
  • 8 Nagasaki F, Flehinger B J, Martini N. Complications of surgery in the treatment of carcinoma of the lung.  Chest . 1982;  82 25-29
    CrossrefPubMedGoogle Scholar
  • 9 Wyser C, Stulz P, Soler M. Prospective evaluation of an algorithm for the functional assessment of lung resection candidates.  Am J Respir Crit Care Med . 1999;  159 1450-1456
    CrossrefPubMedGoogle Scholar
  • 10 Van der Kogel A J. Radiation response and tolerance of normal tissues.  In: Steel GG, ed. Basic Clinical Radiobiology. London: Arnold; . 1997;  30-39
    PubMedGoogle Scholar
  • 11 Movsas B, Raffin T A, Epstein A H. Pulmonary radiation injury.  Chest . 1997;  111 1061-1076
    PubMedGoogle Scholar
  • 12 Davies S D, Yankelevitz D F, Henschke C I. Radiation effects on the lung: Clinical features, Pathology, and Imaging Findings.  AJR . 1992;  159 1157-1164
    PubMedGoogle Scholar
  • 13 Van Houtte P. Mornex P. Radiotherapy of non-small-cell and small-cell and SCLC. Lung cancer. In: Spiro SG, ed. Carcinoma of the Lung. European Respiratory Monograph, vol. 1 Oct. 1995: 241-268
    Google Scholar
  • 14 Fried J R, Goldberg H. Post-irradiation changes in the lung and thorax.  Am J Roentgenol . 1940;  43 877-895
    PubMedGoogle Scholar
  • 15 Ross W M. Radiotherapeutic and radiological aspects of radiation fibrosis of the lungs.  Thorax . 1956;  11 241-246
    PubMedGoogle Scholar
  • 16 Libshitz H I, Southard M E. Complications of radiation therapy: The thorax.  Semin Roentgenol . 1974;  9 41-49
    PubMedGoogle Scholar
  • 17 Roswit B, White D C. Severe radiation injuries of the lung.  AJR . 1977;  129 127-136
    PubMedGoogle Scholar
  • 18 Bate D, Guttemann R J. Changes in the lung and pleura following 2-million volt therapy for carcinoma of the breast.  Radiology . 1957;  69 372-382
    PubMedGoogle Scholar
  • 19 Bachman A L, Macken K. Pleural effusions following supervoltage radiation for breast carcinoma.  Radiology . 1959;  72 699-709
    PubMedGoogle Scholar
  • 20 Libshitz H I, Southard M E. Complications of radiation therapy: The thorax.  Semin Roentgenol . 1974;  9 41-49
    PubMedGoogle Scholar
  • 21 Pagani J J, Libshitz H I. CT manifestations of radiation-induced change in chest tissue.  J Comput Assist Tomogr . 1982;  6 243-248
    PubMedGoogle Scholar
  • 22 Libshitz H I, Shuman L S. Radiation-induced pulmonary change: CT findings.  J Comput Assist Tomogr . 1984;  8 15-19
    PubMedGoogle Scholar
  • 23 Mah K, Poon P Y, Van Dyk J. Assessment of acute radiation-induced pulmonary changes using computed tomography.  J Comput Assist Tomogr . 1986;  10 736-743
    PubMedGoogle Scholar
  • 24 Bourgouin P, Cousineau G, Lemire P. Differentiation of radiation-induced fibrosis from recurrent pulmonary neoplasm by CT.  Can Assoc Radiol J . 1987;  38 23-26
    PubMedGoogle Scholar
  • 25 Ikezoe J, Takashima S, Morimoto S. CT appearance of acute radiation-induced injury in the lung.  AJR . 1988;  150 765-770
    PubMedGoogle Scholar
  • 26 Bell J, McGivern D, Bullimore J. Diagnostic imaging of post-irradiation changes in the chest.  Clin Radiol . 1988;  39 109-119
    CrossrefPubMedGoogle Scholar
  • 27 Frija J, Ferme C, Baud L. Radiation-induced lung injuries: A survey of computed tomography and pulmonary function tests in 18 cases of Hodgkin's disease.  Eur J Radiol . 1988;  8 18-23
    PubMedGoogle Scholar
  • 28 Ikezoe J, Morimoto S, Takashima S. Acute radiation-induced pulmonary injury: Computed tomography evaluation.  Semin Ultrasound CT MR . 1990;  11 409-416
    PubMedGoogle Scholar
  • 29 Glazer H S, Lee J KT, Levitt R G. Radiation fibrosis: Differentiation from recurrent tumor by MR imaging.  Radiology . 1985;  156 721-726
    PubMedGoogle Scholar
  • 30 Kataoka M, Kawamura M, Itho H. Ga-67 citrate scintigraphy for the early detection of radiation pneumonitis.  Clin Nucl Med . 1992;  17 27-31
    PubMedGoogle Scholar
  • 31 Evans R F, Sagerman R H, Ringrose T L. Pulmonary function following mantle-field irradiation for Hodgkin's disease.  Radiology . 1974;  111 729-731
    PubMedGoogle Scholar
  • 32 Brady L W, German P A, Cander L. The effects of radiation therapy on pulmonary function in carcinoma of the lung.  Radiology . 1965;  85 130-134
    PubMedGoogle Scholar
  • 33 Watchie J, Coleman C N, Raffin T A. Minimal long-term cardiopulmonary dysfunction following treatment for Hodgkin's disease.  Int J Radiat Oncol Biol Phys . 1987;  13 517-524
    PubMedGoogle Scholar
  • 34 Lokich J J, Brass H, Eberly F E. The pulmonary effect of mantle irradiation in patients with Hodgkin's disease.  Radiology . 1973;  108 397-402
    PubMedGoogle Scholar
  • 35 Host H, Vale J R. Lung function after mantle field irradiation in Hodgkin's disease.  Cancer . 1973;  32 328-332
    PubMedGoogle Scholar
  • 36 Wolin E M, Rosenberg S A, Kaplan H S. A randomized comparison of PAVe and MOP (P) as adjuvant therapy for Hodgkin's disease. In: Salmon SE, Jones SE, eds. Adjuvant Therapy of Cancer New York: Grune & Stratton, 1979: 119-127
    Google Scholar
  • 37 Rubin O, Casarett G W. Clinical Radiation Pathology.  Philadelphia: WB Saunders, 1968: 423-470
    Google Scholar
  • 38 Gross N J, Narine K R, Wade R. Protective effect of corticosteroids on radiation pneumonitis in mice.  Radiat Res . 1988;  113 112-119
    PubMedGoogle Scholar
  • 39 Gross N J. Pulmonary effects of radiation therapy.  Ann Intern Med . 1977;  86 81-92
    PubMedGoogle Scholar
  • 40 Castellino R A, Glastein E, Turbow M M. Latent radiation injury of lungs or heart activated by steroid withdrawal.  Ann Intern Med . 1974;  80 593-599
    PubMedGoogle Scholar
  • 41 Rotstein S, Blomgren H, Baral E. Incidence of infectious symptoms after radiation therapy for breast cancer: Long-term effects.  Acta Oncol . 1987;  26 197-201
    PubMedGoogle Scholar
  • 42 Gross N j, Holloway N O, Narine K R. Effects of nonsteroidal anti-inflammatory agents on experimental radiation pneumonitis.  Radiat Res . 1991;  127 317-324
    PubMedGoogle Scholar
  • 43 Coggle J E, Lambert B E, Moores S R. Radiation effects in the lung.  Environ Health Perspect . 1986;  70 261-291
    PubMedGoogle Scholar
  • 44 Gross N J. Pulmonary effects of radiation therapy.  Ann Intern Med . 1977;  86 81-92
    PubMedGoogle Scholar
  • 45 Roswitt B, White D C. Severe radiation injuries of the lung.  AJR . 1977;  129 127-136
    PubMedGoogle Scholar
  • 46 Bennett D E, Million R R, Ackerman L V. Bilateral radiation pneumonitis, a complication of the radiotherapy of bronchogenic carcinoma.  Cancer . 1969;  23 1001-1018
    PubMedGoogle Scholar
  • 47 Stone D J, Schwartz M J, Green R A. Fatal pulmonary insufficiency due to radiation effect upon the lung.  Am J Med . 1956;  21 211-226
    CrossrefPubMedGoogle Scholar
  • 48 Whitfield G W, Bond W H, Arnott W M. Radiation reactions in the lung.  Q J Med . 1956;  97 69-86
    PubMedGoogle Scholar
  • 49 Kaufman J, Komorowski R. Bronchiolitis obliterans, a new clinical-pathologic complication of irradiation pneumonitis.  Chest . 1990;  97 1243-1244
    PubMedGoogle Scholar
  • 50 Crestani B, Kambouchner M, Soler P. Migratory bronchiolitis obliterans organizing pneumonia after unilateral radiation therapy for breast carcinoma.  Eur Respir J . 1995;  8 318-321
    CrossrefPubMedGoogle Scholar
  • 51 Bayle J Y, Nesme P, Bejui-Thivolet F. Migratory organizing pneumonitis ``primed'' by radiation therapy.  Eur Respir J . 1995;  8 322-326
    CrossrefPubMedGoogle Scholar
  • 52 Van Laar J M, Holscher H C, Van Krieken J HJM. Bronchiolitis obliterans organizing pneumonia after adjuvant radiotherapy for breast carcinoma.  Respir Med . 1997;  91 241-244
    PubMedGoogle Scholar
  • 53 Crestani B, Valeyre D, Roden S. Bronchiolitis obliterans organising pneumonia syndrome primed by radiation therapy to the breast.  Am J Respir Crit Care Med . 1998;  158 1929-1935
    CrossrefPubMedGoogle Scholar
  • 54 Martin C, Romero S, Sanchez-Paya J. Bilateral lymphocytic alveolitis: A common reaction after unilateral thoracic irradiation.  Eur Respir J . 1999;  13 727-732
    CrossrefPubMedGoogle Scholar
  • 55 Prakash U BS. Radiation-induced injury in the ``nonirradiated'' lung.  Eur Respir J . 1999;  13 715-717
    CrossrefPubMedGoogle Scholar
  • 56 Stewart J R, Fajardo L F. Radiation-induced heart disease: An update.  Prog Cardiovasc Dis . 1984;  27 173-194
    PubMedGoogle Scholar
  • 57 Schultz-Hector S. Heart. In: Scherer E, Streffer C, Trott KR, eds. Radiopathology of Organs and Tissues Berlin: Springer-Verlag, 1991: 347-368
    Google Scholar
  • 58 Brosius F C, Waller B F, Roberts W L. Analysis of 16 young (aged 15-33 years) necropsy patients who received over 3500 rads to the heart.  Am J Med . 1981;  70 519-530
    CrossrefPubMedGoogle Scholar
  • 59 PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: Systematic review and meta-analysis of individual patient data from nine randomised controlled trials.  Lancet . 1998;  352 257-263
    CrossrefPubMedGoogle Scholar
  • 60 Dautzenberg B, Arriagada R, Chammard A B. A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma.  Cancer . 1999;  86 265-273
    CrossrefPubMedGoogle Scholar
  • 61 Van der Kogel AJ. The nervous system: Radiobiology and experimental pathology. In: SchererE, Streffer C, Trott, eds. Radiopathology of Organs and Tissues Heidelberg: Springer-Verlag, 1991: 191-212
    Google Scholar
  • 62 Macbeth F R, Wheldon, T E, Girling D J. Radiation myelopathy: Estimates of risk in 1048 patients in three randomised trials of palliative radiotherapy for non-small cell lung cancer.  Clin Oncol . 1996;  8 176-181
    CrossrefPubMedGoogle Scholar
  • 63 Glantz M J, Choy H, Yee L. Prophylactic cranial irradiation in small cell lung cancer: Rationale, results, and recommendations.  Semin Oncol . 1997;  24 477-483
    PubMedGoogle Scholar
  • 64 Auperin A, Arriagada R, Pignon J P. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission.  N Engl J Med . 1999;  341 476-484
    CrossrefPubMedGoogle Scholar
  • 65 Feld R, Clamon G H, Blunn R. Short course prophylactic cranial irradiation for small cell lung cancer.  Am J Clin Oncol . 1985;  8 371-376
    PubMedGoogle Scholar
  • 66 Posner J B. Neurologic Complications of Cancer.  Philadelphia, PA: FA Davies, 1995: 96-100
    Google Scholar
  • 67 Perez C A, Einhorn L, Oldham R K. Randomized trial of radiotherapy to the thorax in limited small cell carcinoma of the lung treated with multiagent chemotherapy and elective brain irradiation: A preliminary report.  J Clin Oncol . 1984;  2 1200-1208
    PubMedGoogle Scholar
  • 68 Catane R, Schwade J G, Yarr I. Follow-up and neurological evaluation in patients with small cell lung carcinoma treated with prophylactic cranial irradiation and chemotherapy.  Int J Radiat Oncol Biol Phys . 1981;  7 105-109
    PubMedGoogle Scholar
  • 69 Johnson B E, Patronas N, Hayes W. Neurologic, computed cranial tomographic, and magnetic resonance imaging abnormalities in patients with small-cell lung carcinoma: Further follow-up of 6- to 13-year survivors.  J Clin Oncol . 1990;  8 48-56
    PubMedGoogle Scholar
  • 70 Lee J S, Umsawasdi T, Lee Y Y. Neurotoxicity in long-term survivors of small cell lung cancer.  Int J Radiat Oncol Biol Phys . 1986;  12 313-321
    PubMedGoogle Scholar
  • 71 Lishner M, Feld R, Payne D G. Late neurological complications after prophylactic cranial irradiation in patients with small-cell lung cancer: The Toronto experience.  J Clin Oncol . 1990;  8 215-221
    PubMedGoogle Scholar
  • 72 Frytak S, Shaw J N, O'Neill B P. Leukoencephalopathy in small cell lung cancer patients receiving prophylactic cranial irradiation.  Am J Clin Oncol . 1989;  12 27-33
    PubMedGoogle Scholar
  • 73 Ahles T A, Silberfarb P M, Herndon II J. Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin: A study by the Cancer and Leukaemia Group B.  J Clin Oncol . 1998;  16 1954-1960
    PubMedGoogle Scholar
  • 74 Arriagada R, Le Chevalier T, Borie F. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission.  J Natl Cancer Inst . 1995;  87 183-190
    CrossrefPubMedGoogle Scholar
  • 75 Gregor A, Cull A, Stephens R J. Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: Results of a multicentre randomised trial.  Eur J Cancer . 1997;  33 1752-1758
    CrossrefPubMedGoogle Scholar
  • 76 Johnson B E, Cortazar P, Chute J P. Second lung cancers in patients successfully treated for lung cancer.  Semin Oncol . 1997;  24 1-9
    PubMedGoogle Scholar
  • 77 Van Bodegom P Cv, Wagenaar S S, Corrin B. Second primary lung cancer: Importance of long term follow up.  Thorax . 1989;  44 788-793
    PubMedGoogle Scholar
  • 78 Sugimura H, Watanabe S, Tsugane S. Case-control study on histologically determined multiple primary lung cancer.  J Natl Cancer Inst . 1987;  79 435-441
    PubMedGoogle Scholar
  • 79 Mathisen D J, Jensik R J, Faber L P. Survival following resection for second and third primary lung cancers.  J Thorac Cardiovasc Surg . 1984;  82 502-510
    PubMedGoogle Scholar
  • 80 Wu S C, Lin Z Q, Xu C W. Multiple primary lung cancers.  Chest . 1987;  92 892-896
    PubMedGoogle Scholar
  • 81 Deschamps C, Pairolero P C, Trastek V F. Multiple primary lung cancers: Results of surgical treatment.  Ann Thorac Cardiovasc Surg . 1990;  99 769-778
    CrossrefPubMedGoogle Scholar
  • 82 Abrahamsen J F, Andersen A, Hannisdal E. Second malignancies after treatment of Hodgkin's Disease: The influence of treatment, follow-up time, and age.  J Clin Oncol . 1993;  11 255-261
    PubMedGoogle Scholar
  • 83 Swerdlow A J, Douglas A J, Vaughan Hudson G. Risk of second primary cancers after Hodgkin's Disease by type of treatment: Analysis of 2846 patients in the British National Lymphoma Investigation.  Br Med J . 1992;  304 1137-1143
    PubMedGoogle Scholar
  • 84 Tucker M A, Coleman C N, Cox R S. Risk of second cancers after treatment for Hodgkin's Disease.  N Engl J Med . 1988;  318 76-81
    PubMedGoogle Scholar
  • 85 Van Leeuwen F E, Klikman W J, Hagenbeek A. Second cancer risk following Hodgkin's Disease: A 20-year follow-up study.  J Clin Oncol . 1994;  12 312-325
    PubMedGoogle Scholar
  • 86 Kirova Y M, FeuilhadeF, Calitchi E. Radiation-induced sarcoma after breast cancer. Apropos of 8 cases and review of the literature.  Cancer-Radiother . 1998;  2 381-386
    PubMedGoogle Scholar
  • 87 Ihde D c. Drug therapy. Chemotherapy for lung cancer.  N Engl J Med . 1992;  12 1434-1441
    PubMedGoogle Scholar
  • 88 Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials.  Br Med J . 1995;  11 899-909
    PubMedGoogle Scholar
  • 89 Smit E F, Postmus P E. Chemotherapy of small cell lung cancer. In: Carney DN, ed. Lung cancer London: Edward Arnold, 1995: 156-172
    Google Scholar
  • 90 Rosell R, Gomez-Codina J, Camps C. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.  N Engl J Med . 1994;  330 153-158
    CrossrefPubMedGoogle Scholar
  • 91 Roth J A, Fossell F, Komaki R. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer.  J Natl Cancer Inst . 1994;  86 673-680
    CrossrefPubMedGoogle Scholar
  • 92 Weiss R B, Vogelzang N J. Miscellaneous toxicities. In: Devita, VT Jnr, Hellman S, Rosenberg SA, eds. Cancer. Principles and Practice of Oncology Philadelphia: JB Lippincott Company, 1993: 2349-2358
    Google Scholar
  • 93 Steinherz L J, Yahalom J. Cardiac complications of cancer therapy. In: Devita, VT Jnr, Hellman S, Rosenberg SA, eds. Cancer. Principles and Practice of Oncology Philadelphia: JB Lippincott Company, 1993: 2370-2385
    Google Scholar
  • 94 Talcott J A, Finberg R, Mayer R J. The medical course of cancer patients with fever and neutropenia: Clinical identification of a low-risk subgroup at presentation.  Arch Intern Med . 1988;  148 2561-2568
    CrossrefPubMedGoogle Scholar
  • 95 Talcott J A, Siegel R D, Finberg R. Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule.  J Clin Oncol . 1992;  10 316-322
    PubMedGoogle Scholar
  • 96 Freifeld A, Marchigiani D, Walsh T. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy.  N Engl J Med . 1999;  341 305-311
    CrossrefPubMedGoogle Scholar
  • 97 Kern W V, Cometta A, De Bock R. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy.  N Engl J Med . 1999;  341 312-318
    CrossrefPubMedGoogle Scholar
  • 98 Hirsch F R, Hansen H H, Hansen M. The superiority of combination chemotherapy including etoposide based on in vivo cycle analysis in the treatment of small-cell lung cancer: A randomised trial of 288 consecutive patients.  J Clin Oncol . 1987;  5 585-591
    PubMedGoogle Scholar
  • 99 Stephens R J, Girling D J, Machin D. Treatment related deaths in small cell lung cancer trials: Can patients at risk be identified?.  Lung Cancer . 1994;  11 259-274
    CrossrefPubMedGoogle Scholar
  • 100 Morittu L, Earl H M, Souhami R L. Patients at risk of chemotherapy-associated toxicity in small cell lung cancer.  Br J Cancer . 1989;  59 801-804
    PubMedGoogle Scholar
  • 101 Johnson D H. Small cell lung cancer in the elderly patient.  Semin Oncol . 1997;  24 484-491
    PubMedGoogle Scholar
  • 102 Urban T, Lebeau B. Colony-stimulating factor therapy and febrile neutropenia induced by chemotherapy: Need for economical studies.  Eur Respir J . 1999;  13 1228-1229
    PubMedGoogle Scholar
  • 103 Crawford J, Ozer H, Stoller R. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.  N Engl J Med . 1991;  325 164-170
    CrossrefPubMedGoogle Scholar
  • 104 Trillet-Lehoir V, Green J, Manegold C. Recombinant granulocyte colony-stimulating factor reduces the infectious complications of cytotoxic chemotherapy.  Eur J Cancer . 1993;  29 319-324
    CrossrefPubMedGoogle Scholar
  • 105 Maher D W, Lieschke G J, Green M. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial.  Ann Intern Med . 1994;  121 492-501
    PubMedGoogle Scholar
  • 106 Mayordomo J I, Rivera F, Diaz-Puente M. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors.  J Natl Cancer Inst . 1995;  87 803-808
    PubMedGoogle Scholar
  • 107 Anaissie E J, Vartivarian S, Bodey G P. Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) in cancer patients with fever and neutropenia.  Am J Med . 1996;  100 17-23
    CrossrefPubMedGoogle Scholar
  • 108 Cooper J AD, White D A, Matthay R A. Drug-induced pulmonary disease. Part 1: Cytotoxic drugs.  Am Rev Respir Dis . 1986;  133 321-340
    PubMedGoogle Scholar
  • 109 Israel-Biet D, Labrune S, Huchon, G J. Drug-induced lung disease: 1990 review.  Eur Respir J . 1991;  4 465-478
    PubMedGoogle Scholar
  • 110 Foucher P, Biour M, Blayac J P. Drugs which may injure the respiratory system.  Eur Respir J . 1997;  10 265-279
    CrossrefPubMedGoogle Scholar
  • 111 Hesketh P J, Gandara. A new class of antiemetic agents.  J Natl Cancer Inst . 1991;  83 613-620
    PubMedGoogle Scholar
      >